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Sir,
In a recent case–control study from Uganda, Newton et al
(2002) reported the odds ratios for conjunctival carcinoma in
relation to HPV-16 were 1.0 for anti-HPV-16 antibody negative
(baseline group), 0.7 (0.2–2.9) for medium titre and 6.3 (1.2–33.4)
for high-titre infection (Ptrend¼0.2). It was concluded that there
was insufficient evidence to support a role for HPV-16 in the
aetiology of conjunctival cancer. We have now investigated the
issue further in Uganda, using the same assay for HPV-16
antibodies as used in the earlier study. From November 1995 to
May 2001, all patients with a provisional diagnosis of conjunctival
squamous cell neoplasia who presented to a single surgeon (KW)
in ophthalmology clinics throughout Uganda were recruited for
study. After informed consent was obtained, tests for human
immunodeficiency virus-1 (HIV) infection were offered and
pretest counselling provided. Sociodemographic and clinical
details were recorded from all the participants. HIV test results
were reported back to the patients, together with post-test
counselling and any remaining plasma was stored at minus 401C.
The study was approved by the Uganda National Council for
Science and Technology and by the Science and Ethics Committee
of the Uganda Virus Research Institute.
Appropriate treatment was provided to all the participants.
Excised tumours were fixed in formal saline and sent to St Thomas’
Hospital London for histopathological review by a single
pathologist (SL). Conjunctival intraepithelial neoplasia (CIN) was
classified into three stages as dysplasia occupying one-, two- or
three-thirds of the epithelial thickness (CIN I–III; CIN III is
synonymous with carcinoma in situ). Plasma samples were
shipped on dry ice to the Laboratoire de Virologie Mole ´culaire,
in Tours, France, where they were tested for antibodies against
HPV-16, in a blinded fashion, using methods described
elsewhere (Newton et al, 2002). Patient information and test
results were recorded onto EPI-INFO (Dean et al, 1990) software
and statistical analyses were conducted using STATA (STATA
Corp., 2001).
From a total of 476 patients, 291 had enough stored plasma for
anti-HPV-16 antibody testing, but following histological review, 37
of the 291 turned out to have diagnoses other than conjunctival
neoplasia, such as pingueculae and inflammatory lesions. These
individuals comprise the control group in analyses of the
prevalence of anti-HPV-16 antibodies. The odds of anti-HPV-16
antibodies were compared between cases and controls, using odds
ratios, estimated with unconditional logistic regression, adjusting
for age group (o25, 25–34, 34þ years), sex and HIV serostatus.
The seroprevalence of HIV infection was 67% (169 of 254)
among cases and 35% (13 of 37) among controls. The prevalence of
antibodies against HPV-16 was 15% (37 of 254) among those with
conjunctival neoplasia and 16% (six of 37) among controls (odds
ratio 1.1, 95% confidence intervals 0.4–2.9). Table 1 shows the
prevalence of anti-HPV-16 antibodies according to the titre and
the histological stage of conjunctival neoplasia, stratified by HIV
serostatus. Table 2 shows the odds ratio for conjunctival neoplasia
associated with a measure of anti-HPV-16 antibody titre, stratified
by HIV serostatus. We find no evidence of a statistically significant
association between anti-HPV-16 antibody status and the risk of
conjunctival neoplasia. Although its statistical power is low, this
study supplements the information already reported by Newton
et al (2002). Specifically designed larger studies offer most hope of
identifying any underlying infectious cause of conjunctival
neoplasia.
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Table 1 Prevalence of anti-HPV-16 antibodies among cases and controls
Diagnosis
Percentage with
anti-HPV-16 antibodies
(number positive/total)
Percentage with medium
titres of anti-HPV-16 antibodies
(number positive/total)
Percentage with
high titres of
anti-HPV-16 antibodies
(number positive/total)
All Subjects
Controls 16% (6/31) 14% (5/37) 3% (1/37)
Cases
Total 15% (37/254) 8% (21/254) 6% (16/254)
CIN I 18% (5/28) 11% (3/28) 7% (2/28)
CIN II 15% (5/34) 12% (4/34) 3% (1/34)
CIN III 14% (12/84) 7% (6/84) 7% (6/84)
Invasive 14% (15/108) 7% (8/108) 6% (7/108)
HIV-seronegative subjects
Controls 21% (5/24) 17% (4/24) 4% (1/24)
Cases
Total 15% (13/85) 8% (7/85) 7% (6/85)
CIN I 8% (1/12) 0% (0/12) 8% (1/12)
CIN II 9% (1/11) 0% (0/11) 9% (1/11)
CIN III 17% (5/29) 10% (3/29) 7% (2/29)
Invasive 18% (6/33) 12% (4/33) 6% (2/33)
HIV-seropositive subjects
Controls 8% (1/13) 8% (1/13) 0% (0/13)
Cases
Total 14% (24/169) 8% (14/169) 6% (10/169)
CIN I 25% (4/16) 19% (3/16) 6% (1/16)
CIN II 17% (4/23) 17% (4/23) 0% (0/23)
CIN III 13% (7/55) 5% (3/55) 7% (4/55)
Invasive 12% (9/75) 5% (4/75) 7% (5/75)
Table 2 Summary of the association between a measure of anti-HPV-16 antibody titre and the risk of conjunctival neoplasia
HIV seronegative HIV seropositive All subjects
Anti-HPV-16 antibody status
Odds ratio and 95%
confidence intervals
a
Odds ratio and 95%
confidence intervals
a
Odds ratio and 95%
confidence intervals
b
Seronegative 1.0 1.0 1.0
Seropositive–low titre 0.5 (0.1–1.9) 1.2 (0.1–10.7) 0.6 (0.2–2.0)
Seropositive–high titre 2.2 (0.2–20.8) ˜ 3.3 (0.4–27.6)
w
2 trend (1 d.f.)¼0.0 w
2 trend (1 d.f.)¼0.8 w
2 trend (1 d.f.)¼0.4
P¼0.9 P¼0.4 P¼0.5
aOdds ratios adjusted for age group (o25, 25–34, 34+years) and sex.
bOdds ratios adjusted for age group, sex and HIV serostatus. d.f.¼degrees of freedom.
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